Single-dose surgical prophylaxis using ticarcillin/clavulanic acid (Timentin): a prospective, randomized comparison with cefotaxime.
Single 3.1-g dose surgical prophylaxis with ticarcillin/clavulanic acid (Timentin) was compared to single-dose cefotaxime. Among 224 evaluable cases, the Timentin associated wound infection rate (0.7%), nonwound infectious morbidity (8.8%), adverse reactions (1.9%), and total costs ($14.15) were not statistically different than that of the control drug. The beta-lactamase [corrected] inhibitor combination reported herein should be considered along with other beta-lactams [corrected] for use as a cost-effective, single-dose surgical prophylaxic agent on a wide variety of operative procedures.
D000328:Adult; D002439:Cefotaxime / Q000008:administration & dosage / Q000627:therapeutic use*; D002969:Clavulanic Acids / Q000008:administration & dosage / Q000627:therapeutic use*; D004338:Drug Combinations / Q000008:administration & dosage / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008297:Male; D010406:Penicillins / Q000627:therapeutic use*; D011292:Premedication; D011446:Prospective Studies; D011897:Random Allocation; D013530:Surgical Wound Infection / Q000517:prevention & control; D013982:Ticarcillin / Q000008:administration & dosage / Q000627:therapeutic use*
D002969:Clavulanic Acids; D004338:Drug Combinations; D010406:Penicillins; C043215:ticarcillin-clavulanic acid; D013982:Ticarcillin; D002439:Cefotaxime